相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Case report: First report of isolated central nervous system lymphoblastic crisis in a child with chronic myeloid leukemia on dasatinib therapy
Suejung Jo et al.
FRONTIERS IN ONCOLOGY (2023)
Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
Haruko Shima et al.
PEDIATRIC BLOOD & CANCER (2022)
Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
Yeojae Kim et al.
FRONTIERS IN PEDIATRICS (2022)
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
Naranie Shanmuganathan et al.
BLOOD (2021)
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
Frederic Millot et al.
CANCERS (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
Shinya Kimura et al.
LANCET HAEMATOLOGY (2020)
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Jorge E. Cortes et al.
LEUKEMIA (2020)
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
Uros Markovic et al.
ANTICANCER RESEARCH (2020)
Chronic Myeloid Leukemia, Version 2.2021
Michael W. Deininger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
How I treat chronic myeloid leukemia in children and adolescents
Nobuko Hijiya et al.
BLOOD (2019)
Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group
Uma Athale et al.
PEDIATRIC BLOOD & CANCER (2019)
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Meinolf Suttorp et al.
LEUKEMIA (2018)
Association Between Insurance Status at Diagnosis and Overall Survival in Chronic Myeloid Leukemia: A Population-Based Study
Ashley M. Perry et al.
CANCER (2017)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
Neil P. Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis et al.
PEDIATRIC BLOOD & CANCER (2016)
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Timothy P. Hughes et al.
BLOOD (2014)
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2014)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
Michael Lauseker et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
F. Giona et al.
HAEMATOLOGICA (2012)
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia
Maynika V. Rastogi et al.
PEDIATRIC BLOOD & CANCER (2012)
分享论文
